Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like Infliximab (IFX), presents numerous challenges for gastroenterologists. Despite the widespread use of IFX, a significant proportion of patients experience a loss of response over time – often within the first…
IV Infliximab, a monoclonal antibody, has emerged as an efficient treatment with many clinical benefits, such as quick disease activity reduction and IBD patient life quality improvement. However, drug development of infliximab using weight-based dosing of MAbs without consideration of…
Inflammatory Bowel Disease (IBD) represents a group of chronic intestinal conditions, such as ulcerative colitis and Crohn’s disease. These disorders cause prolonged inflammation in the digestive tract, leading to uncomfortable and sometimes unpredictable symptoms. Living with IBD can be a…
